# ScoreItem: Anti-LA (SSB)

**ID:** `019bf31d-2ef0-7f55-91a7-5c6b22ee5315`
**FullName:** Anti-LA (SSB) (Exames - Laboratoriais)

**Preparation Metadata:**
- Quality Grade: **FAIR**
- Total Chunks: 30 de 18 artigos
- Avg Similarity: 0.465

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7f55-91a7-5c6b22ee5315`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7f55-91a7-5c6b22ee5315",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Anti-LA (SSB) (Exames - Laboratoriais)

**30 chunks de 18 artigos (avg similarity: 0.465)**

### Chunk 1/30
**Article:** Remiss√£o do L√∫pus Atrav√©s da Medicina Funcional Integrativa (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.524

glicoprote√≠na, anticoagulante l√∫pico). A combina√ß√£o destes tem um peso que define o diagn√≥stico.
    - **L√∫pus (2019):** O crit√©rio de entrada √© um FAN (ANA) positivo com t√≠tulo m√≠nimo de 1 para 80. A este somam-se outros sinais cl√≠nicos e laboratoriais para atingir um score diagn√≥stico.
    - **SLEDAI:** √â uma m√©trica para avaliar a atividade da doen√ßa. Atribui um peso a diversos sinais e sintomas (de neurol√≥gicos a osteomusculares) para classificar a atividade como leve, moderada ou grave, orientando o tratamento.
    - **DORES (2021):** S√£o as defini√ß√µes de remiss√£o para o l√∫pus. Exigem um score zero no SLEDAI (sem sintomas cl√≠nicos) e uma avalia√ß√£o m√©dica compat√≠vel, independentemente do uso de medica√ß√£o ou da presen√ßa de autoanticorpos.
### 3. Pilares para a Remiss√£o na Medicina Funcional
*   **Dieta Anti-inflamat√≥ria**
    - **Exposi√ß√£o Solar e Vitamina D:** A fotossensibilidade √© um crit√©rio do l√∫pus, exigindo fotoprote√ß√£o.

---

### Chunk 2/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.497

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 3/30
**Article:** Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe Graves' orbitopathy (2023)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.495

oassaysforTSH-receptorautoantibodies:anupdate.AutoimminRev(2010)10(2):116‚Äì22.doi:10.1016/j.autrev.2010.08.01819.BartalenaL,VeronesiG,KrassasGE,WiersingaWM,MarcocciC,Marin√≤M,etal.Doesearlyresponsetointravenousglucocorticoidspredictthenaloutcomeinpatientswithmoderate-to-severeandactivegraves‚Äôorbitopathy?JEndocrinolInvest(2017)40(5):547‚Äì53.doi:10.1007/s40618-017-0608-z20.AhnHY,LeeJK.IntravenousglucocorticoidtreatmentforKoreangraves‚Äôophthalmopathypatients.JKoreanMedSci(2020)35(23).doi:10.3346/jkms.2020.35.e17721.LanzollaG,SabiniE,ProloM,MazziB,SframeliA,RocchiR,etal.Relationshipbetweenserumcholesterolandgraves‚Äôorbitopathy(GO):aconrmatorystudy.JEndocrinolInvest.(2018)41(12):1417‚Äì23.doi:10.1007/s40618-018-0915-z22.SabiniE,MazziB,ProloMA,MautoneT,CasiniG,RocchiR,etal.Highserumcholesterolisanovelriskfactorforgraves‚Äôorbitopathy:resultsofacross-sectionalstudy.Thyroid(2018)28(3):386‚Äì94.doi:10.1089/thy.2017.043023.ChinYH,NgCH,LeeMH,KohJWH,KiewJ,YangSP,etal.Prevalenceofthyroide

---

### Chunk 4/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.492

ent. Periodic controls are necessary for the early detection of 
characteristic complications. Hopefully, with the emergence of new 
treatment options and proper high-quality studies, the pathogenetic and 
therapeutic landscape of LS will improve in the near future.
Author contributions
All authors listed have made a substantial, direct, and intellectual 
contribution to the work and approved it for publication.
Funding
Funding sources from Cluster of Excellence Precision Medicine in 
Chronic Inammation (EXC 2167) and the Research Training Group 
Autoimmune Pre-Disease (GRK 2633), all from the Deutsche 
Forschungsgemeinscha; and the Schleswig-Holstein Excellence-Chair 
Program from the State of Schleswig Holstein.

---

### Chunk 5/30
**Article:** Remiss√£o do L√∫pus Atrav√©s da Medicina Funcional Integrativa (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.482

os Cl√≠nicos em Reumatologia
*   **Crit√©rios de Classifica√ß√£o vs. Diagn√≥stico**
    - Os crit√©rios de classifica√ß√£o s√£o defini√ß√µes padronizadas usadas para estudos cl√≠nicos, com alta especificidade (poucos falsos positivos) e baixa sensibilidade (mais falsos negativos), ideais para uniformizar coortes de pesquisa.
    - Os crit√©rios de diagn√≥stico s√£o conjuntos de sinais, sintomas e testes usados na rotina cl√≠nica para o cuidado do paciente, com alta sensibilidade e especificidade.
*   **Crit√©rios Espec√≠ficos**
    - **SAF (2023):** Os crit√©rios classificat√≥rios do Col√©gio Americano e da Liga Europeia de Reumatologia exigem a presen√ßa de crit√©rios cl√≠nicos (macro/microvascular, obst√©trico, hematol√≥gico, cardiol√≥gico) e laboratoriais (anticardiolipina, anti-beta-2-glicoprote√≠na, anticoagulante l√∫pico). A combina√ß√£o destes tem um peso que define o diagn√≥stico.

---

### Chunk 6/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.480

study in the all of us research program. 
Br 
J Dermatol
. (2022) 187:797¬ñ9. doi: 
10.1111/bjd.21702
. [Epub ahead of print]

DeLuca et al. 
10.3389/fmed.2023.1106318
Frontiers in 
Medicine
18
frontiersin.org
 113. Arousse, A, Boussofara, L, Mokni, S, Gammoudi, R, Saidi, W, Aounallah, A, et al. 
Alopecia areata in Tunisia: epidemio-clinical aspects and comorbid conditions. A 
prospective study of 204 cases. 
Int J Dermatol
. (2019) 58:811¬ñ5. doi: 
10.1111/ijd.14381
 114. Miraglia, E, Calvieri, S, and Giustini, S. Lichen sclerosus and sj√∂gren's syndrome. 
Ital J Dermatol Venerol
. (2021) 156:63¬ñ4. doi: 
10.23736/S2784-8671.19.06362-4
 115. Stagi, S, Gasperini, S, Manoni, C, Greco, A, Funghini, S, and Donati, A. 
Autoimmune thyroiditis, pernicious anaemia, vitiligo and scleroatrophic lichen in a boy 
with short-chain acylCoA dehydrogenase deciency. 
Horm Res Paediatr
. (2010) 73:409¬ñ13. 
doi: 
10.1159/000308176
 116. McGrath, EJ, and Davies, MG.

---

### Chunk 7/30
**Article:** Remiss√£o do L√∫pus Atrav√©s da Medicina Funcional Integrativa (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.477

alizados.
  - **Set/2022:** Anticoagulante l√∫pico ausente; anticardiolipina IgG negativa.
  - **Mai/2023:** FAN negativo.
## Diagn√≥stico Prim√°rio:
- Avalia√ß√£o: L√∫pus Eritematoso Sist√™mico (LES) e S√≠ndrome do Anticorpo Antifosfolip√≠dio (SAF) em remiss√£o cl√≠nica, medicamentosa e laboratorial consolidada.
- Diagn√≥stico Suspeito: Nenhum no momento.
## Plano:
- Prescri√ß√£o: Inserir mais aqui.
- Pr√≥ximas Etapas e Exames:
  - Continuidade da forma√ß√£o em medicina funcional integrativa, incluindo m√≥dulo de imunologia pelo IFM.
- Plano de Acompanhamento:
  - Manter dieta anti-inflamat√≥ria (sem gl√∫ten, sem latic√≠nios e com baixo teor de a√ß√∫car).
  - Praticar atividade f√≠sica regularmente (Pilates).
  - Gerenciar estresse com rotina organizada, sono de qualidade e autocuidado.
  - Manter suplementa√ß√£o (vitamina D essencial para pacientes com l√∫pus).
  - Realizar fotoprote√ß√£o rigorosa, preferindo filtros f√≠sicos.

---

### Chunk 8/30
**Article:** SAM (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.475

ores H1 e H2).
    *   **Dosagem:** Pacientes com SAM podem necessitar de doses at√© quatro vezes maiores que as recomendadas na bula, com escalonamento gradual.
    *   **Suplementa√ß√£o e Alternativas:** Podem ser √∫teis: Vitaminas C, D, E, magn√©sio, probi√≥ticos e flavonoides (quercetina, luteolina). Curcumina e extrato de canela tamb√©m mostram evid√™ncias, mas com cautela.
    *   **Casos Graves:** A terapia com imunobiol√≥gicos (omalizumabe) √© uma op√ß√£o.
*   **Import√¢ncia do Diagn√≥stico:** O diagn√≥stico √© libertador para o paciente, pois valida seus sintomas e permite a busca por tratamento adequado. O profissional de sa√∫de deve reconhecer a possibilidade da SAM e, se necess√°rio, encaminhar o paciente a um especialista. O tratamento deve focar na causa, investigando a fundo a hist√≥ria cl√≠nica e os gatilhos individuais.
## ‚ùì Perguntas
- [Inserir Pergunta/D√∫vida]
## üìö Tarefas
- [ ] 1.

---

### Chunk 9/30
**Article:** Long COVID: Complications, Underlying Mechanisms, and Treatment Strategies (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.473

beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with Covid-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med 9 (2021): 1365‚Äì76. [PubMed: 34672949] 
114. Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 384 (2021): 497‚Äì511. [PubMed: 33264556] 
Zadeh et al.Page 31
Arch Microbiol Immunol. Author manuscript; available in PMC 2023 June 29.
Author ManuscriptAuthor ManuscriptAuthor ManuscriptAuthor Manuscript
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

115. Harzallah I, Debliquis A, Drenou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 18 (2020): 2064‚Äì5. [PubMed: 32324958] 
116. Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al.

---

### Chunk 10/30
**Article:** Evaluation of the diagnostic performance of thyroid-stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease (2023)
**Journal:** J Clin Lab Anal
**Section:** discussion | **Similarity:** 0.469

J Clin Lab Anal. 2023;37:e24890.				‚ÄÉ|‚ÄÉ1 of 7https://doi.org/10.1002/jcla.24890
wileyonlinelibrary.com/journal/jcla
Received:	7	November	2022‚ÄÉ|‚ÄÉRevised:	3	March	2023‚ÄÉ|‚ÄÉAccepted:	14	April	2023DOI: 10.1002/jcla.24890  
RESEARCH ARTICLEEvaluation of the diagnostic performance of thyroid- 
stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' diseaseShiji¬†Xu‚ÄÉ|¬†¬†¬†Wenqi¬†Shao‚ÄÉ|¬†¬†¬†Qun¬†Wu‚ÄÉ|¬†¬†¬†Jing¬†Zhu‚ÄÉ|¬†¬†¬†Baishen¬†Pan‚ÄÉ|   Beili Wang
‚ÄÉ|   Wei Guo
This is an open access article under the terms of the Creative	Commons	Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.¬©	2023	The	Authors.	Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Shiji Xu and Wenqi Shao contributed equally to this work. Shiji Xu and Wenqi Shao share the first authorship.

---

### Chunk 11/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.468

Lp(a), APO-B/APO-A, NO) para preven√ß√£o e tratamento da DCV.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Solicitar avalia√ß√£o do √≠ndice de √¥mega 3 e da raz√£o √¥mega 3:√¥mega 6; ajustar suplementa√ß√£o de √¥mega 3 conforme resultados.
- [ ] 2. Dosar vitamina D (25(OH)D) e PTH; estabelecer metas de 80 ng/mL para cardiopatas/hipertensos e considerar >100 ng/mL para autoimunes, com monitoriza√ß√£o de seguran√ßa.
- [ ] 3. Aplicar protocolo de curva de glicose e insulina (jejum, 30, 60, 90, 120 min) para detectar hiperinsulinemia oculta e resist√™ncia √† insulina.
- [ ] 4. Introduzir metformina em casos de resist√™ncia √† insulina, juntamente com plano nutricional coordenado com nutricionista.
- [ ] 5. Avaliar homociste√≠na e intervir com vitaminas B9, B12 e B6 em casos de eleva√ß√£o, considerando polimorfismos de metila√ß√£o.
- [ ] 6.

---

### Chunk 12/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.467

controls (
108
). e 
BMZ demonstrates an alteration of the antigen expression, 
augmented collagen IV and VII, and loss of expression of 
hemidesmosomal and anchoring lament components. As a result of 
these changes, the BMZ is disrupted or some areas of BMZ are 
completely absent (
109
).
The immunohistochemistry approach shows a dense infiltrate 
of CD4+ and CD8+ T-cells, localized in the subepidermal 
inflammatory band. In certain cases, the T-cells also infiltrate the 
dermoepidermal junction, lower epidermis and dermis. CD68+ 
macrophages are present in the inflammatory band and also 
scattered throughout sclerotic regions. HLA-DR is also expressed, 
in variable percentages, in the inflammatory infiltrates and 
keratinocytes (
48
).
7. Associations
Autoimmune diseases are associated with LS in more than a quarter 
of the patients (
110
).

---

### Chunk 13/30
**Article:** Evaluation of the diagnostic performance of thyroid-stimulating immunoglobulin and thyrotropin receptor antibodies for Graves' disease (2023)
**Journal:** J Clin Lab Anal
**Section:** other | **Similarity:** 0.462

ypothyroidism	and	in	98	TSAb-	ÔøΩpositive	Graves'	patients	with	hyperthyroidism:	reevalua-tion	of	TSBAb	and	TSAb	in	TSH-	ÔøΩreceptor-	ÔøΩantibody	(TRAb)-	ÔøΩpositive	patients. J Thyroid Res. 2012;2012:182176.	14.	Tong	M,	Ding	J,	Huang	B,	et	al.	Evaluation	of	the	application	of TSH receptor stimulating autoantibodies and the optimi-zation	of	detection	strategy	in	Graves'	disease.	Clin Chim Acta. 2021;521:34-	ÔøΩ39.
How¬†to¬†cite¬†this¬†article:¬†Xu S, Shao W, Wu Q, et al. Evaluation of	the	diagnostic	performance	of	thyroid-	ÔøΩstimulating	immunoglobulin and thyrotropin receptor antibodies for Graves'	disease.	J Clin Lab Anal. 2023;37:e24890. doi:10.1002/jcla.24890

---

### Chunk 14/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** methods | **Similarity:** 0.462

spectrom-etry methodsAt least 1 year of amenorrheaDouble-blind, randomized, placebo-con-trolled trialPlaceboForsblad-d¬íElia, H2009Swedenpostmeno-pausal women with primary Sjogrens syn-drome60.723/239 months50Estradiol, testos-teroneHP5973 quadrupole mass spectrom-eter equipped with a chemical ionization sourceNot reportedDouble-blind placebo-controlled cross-overPlaceboJankowski, C. M2008USApostmeno-pausal older women6925/3312 months50Estradiol, testos-teroneRadioimmu-noassayAt least 1 year of amenorrheaDouble-blind, randomized, placebo-con-trolled trialPlaceboIgwebuike, A2008USApostmenopau-sal women64.5917/1712 weeks50Estradiol, testos-teroneChemilumines-cence immuno-assaysAt least 1 year of amenorrheaDouble-blind, randomized, placebo-con-trolled trialPlaceboVillareal, D.

---

### Chunk 15/30
**Article:** Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe Graves' orbitopathy (2023)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.460

lesterolisanovelriskfactorforgraves‚Äôorbitopathy:resultsofacross-sectionalstudy.Thyroid(2018)28(3):386‚Äì94.doi:10.1089/thy.2017.043023.ChinYH,NgCH,LeeMH,KohJWH,KiewJ,YangSP,etal.Prevalenceofthyroideyediseaseingraves‚Äôdisease:ameta-analysisandsystematicreview.ClinEndocrinol(Oxf)(2020)93(4):363‚Äì74.doi:10.1111/cen.1429624.KimBR,KimJ,LeeJE,LeeEJ,YoonJS.Therapeuticeffectofguggulsteroneinprimaryculturedorbitalbroblastsobtainedfrompatientswithgraves‚Äôorbitopathy.InvestOphthalmolVisSci(2020)61(3):39.doi:10.1167/iovs.61.3.3925.XingL,YeL,ZhuW,ShenL,HuangF,JiaoQ,etal.Smokingwasassociatedwithpoorresponsetointravenoussteroidstherapyingraves‚Äôophthalmopathy.BrJOphthalmol(2015)99(12):1686‚Äì91.doi:10.1136/bjophthalmol-2014-30646326.AziziF,AmouzegarA,TohidiM,HedayatiM,KhaliliD,CheraghiL,etal.Increasedremissionratesafterlong-termmethimazoletherapyinpatientswithgraves‚Äôdisease:resultsofarandomizedclinicaltrial.Thyroid(2019)29(9):1192‚Äì200.doi:10.1089/thy.2019.018027.LaurbergP,BermanDC,Andersen

---

### Chunk 16/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.459

ociety. 
http://www.cancer.org/cancer/breastcancer/
).
311. Van Vollenhoven RF,
 
Engleman EG,
 
McGuire JL.
 
An open study of
dehydroepiandrosterone in systemic lupus erythematosus.Arthritis Rheum
 
1994;
 
37:
 
1305‚Äì
10
312. Van Vollenhoven RF,
 
Engleman EG,
 
McGuire JL.
 
Dehydroepiandrosterone in systemic
lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical
trial.
 
Arthritis Rheum
 
1995;
 
38:
 
1826‚Äì31
313. Van Vollenhoven RF,
 
Morabito LM,
 
Engleman EG,
 
McGuire JL.
 
Treatment of systemic
lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
 
J
Rheumatol
 
1998;
 
25:
 
285‚Äì9
314. Van Vollenhoven RF,
 
Park JL,
 
Genovese MC,
 
West JP,
 
McGuire JL.
 
A double-blind,
placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus
erythematosus.
 
Lupus
 
1999;
 
8:
 
181‚Äì7
315. Mease PJ,
 
Merril JT,
 
Lahita RG,
 
et al.

---

### Chunk 17/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.458

.
e etiology and pathogenesis of LS are still not fully elucidated. ere is a genetic and familial 
predisposition in LS, whereas frequent trauma, hormonal status and certain drugs could also play a 
role in the pathogenesis. LS is a type 1 T helper (1) mediated and miR-155 dependent immune-
mediated disease. Although autoantibodies against extracellular matrix protein 1 and BP180 have 
been described, it is still unclear if they represent an accurate piece of LS pathogenesis. ere is also 
OPEN ACCESS
EDITED BY
Aikaterini Patsatsi, 
 
Aristotle University of Thessaloniki, Greece
REVIEWED BY
Gianpaolo Tessari, 
 
Integrated University Hospital Verona, 
 
Italy
Anca Chiriac, 
 
Apollonia University, 
 
Romania
*CORRESPONDENCE
David A.

---

### Chunk 18/30
**Article:** Intoler√¢ncias, Alergias e Hipersensibilidades Alimentares II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.456

ambos ‚Üí ~80%.
- Tipo de parto, aleitamento materno exclusivo e uso precoce de mamadeira.
- Exame f√≠sico: dor √† palpa√ß√£o da fossa il√≠aca direita pode sugerir inflama√ß√£o em placas de Peyer.
- Colonoscopia: hiperplasia nodular linf√≥ide no √≠leo terminal (achado associado, n√£o espec√≠fico).
- Manifesta√ß√µes orais: aftas, prurido far√≠ngeo, dermatite perioral, l√≠ngua geogr√°fica; palidez facial sem anemia; refluxo, v√¥mitos, dor abdominal cr√¥nica recorrente.
### 13. Sinais e sintomas associados √† alergia alimentar (ampliados)
- Gastrointestinais: constipa√ß√£o, sangramento oculto, anemia, diarreia, m√° absor√ß√£o de gordura.
- Respirat√≥rios: broncoespasmo, coriza, tosse.
- Cut√¢neos: dermatite at√≥pica, urtic√°ria, angioedema, palidez facial.
- Neurol√≥gicos/comportamentais: hiperatividade, d√©ficit de aten√ß√£o.
### 14.

---

### Chunk 19/30
**Article:** Selective IgA Deficiency (2023)
**Journal:** StatPearls Publishing
**Section:** abstract | **Similarity:** 0.455

Guia cl√≠nico abrangente sobre defici√™ncia seletiva de IgA, a imunodefici√™ncia prim√°ria mais comum. Cobre epidemiologia, fisiopatologia, apresenta√ß√£o cl√≠nica, diagn√≥stico, manejo e progn√≥stico. Principais achados: Diagn√≥stico requer IgA s√©rica < 7 mg/dL (< 0,07 g/L) com IgG e IgM normais em pacientes > 4 anos; Maioria dos pacientes permanece assintom√°tica ao longo da vida; 20-30% dos pacientes desenvolvem doen√ßas autoimunes concomitantes; Precau√ß√µes especiais necess√°rias em transfus√µes sangu√≠neas devido a anticorpos anti-IgA; Tratamento inclui antibi√≥ticos profil√°ticos e monitoramento peri√≥dico.

---

### Chunk 20/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.454

d with LS in more than a quarter 
of the patients (
110
). In a large retrospective study, autoimmune thyroid 
diseases such as Hashimoto¬ís thyroiditis and Graves¬í disease, antithyroid 
antibodies and elevated autoantibodies were more commonly associated 
with female LS (18.9%) than male patients (5.1%) (
111
). In a case¬ñ
control study of 765 cases of VLS, it was found a 2.88-, 2.34-, and 2.05-
fold increase in odds of having autoimmune thyroiditis, hypothyroidism, 
and hyperthyroidism, respectively. is study provides further evidence 
that screening for thyroid disorders in LS patients should 
beconsidered (
112
).
ere are also reports from vitiligo, alopecia areata, rheumatoid 
arthritis, pernicious anemia, systemic lupus erythematosus, Sj√∂gren 
syndrome, and multiple sclerosis (
110
,
 
111
,
 
113
¬ñ
116
). In 5.7% of 
patients, morphea coexists with LS, especially the circumscribed and 
generalized types (
117
).

---

### Chunk 21/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.454

.DiabetesRev.2020,16,442‚Äì449.[CrossRef]56.Hueber,W.;Robinson,W.H.Proteomicbiomarkersforautoimmunedisease.Proteomics2006,6,4100‚Äì4105.[CrossRef]57.Enocsson,H.;Gullstrand,B.;Eloranta,M.-L.;Wetter√∂,J.;Leonard,D.;R√∂nnblom,L.;Bengtsson,A.A.;Sj√∂wall,C.C-ReactiveProteinLevelsinSystemicLupusErythematosusAreModulatedbytheInterferonGeneSignatureandCRPGenePolymorphismrs1205.Front.Immunol.2021,11,3730.[CrossRef]58.Wium-Andersen,M.K.;√òrsted,D.D.;Nielsen,S.F.;Nordestgaard,B.G.ElevatedC-ReactiveProteinLevels,PsychologicalDistress,andDepressionin73131Individuals.JAMAPsychiatry2013,70,176‚Äì184.[CrossRef]59.Chamberlain,S.R.;Cavanagh,J.;deBoer,P.;Mondelli,V.;Jones,D.N.;Drevets,W.C.;Cowen,P.J.;Harrison,N.A.;Pointon,L.;Pariante,C.M.;etal.Treatment-resistantdepressionandperipheralC-reactiveprotein.Br.J.Psychiatry2018,214,11‚Äì19.[CrossRef]60.Ma,Y.;Chiriboga,D.E.;Pagoto,S.L.;Rosal,M.C.;Li,W.;Merriam,P.A.;H√©bert,J.R.;Whited,M.C.;Ockene,I.S.AssociationbetweenDepressionandC-ReactiveProtein.Cardiol.Res.

---

### Chunk 22/30
**Article:** Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe Graves' orbitopathy (2023)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.454

inAK,PlichtM,LaxH,Neuha√ºuserM,MannK,LederbogenS,etal.Thyrotropinreceptorautoantibodiesareindependentriskfactorsforgraves‚Äôophthalmopathyandhelptopredictseverityandoutcomeofthedisease.JClinEndocrinolMetab(2006)91(9):3464‚Äì70.doi:10.1210/jc.2005-281311.MouritsMP,PrummelMF,WiersingaWM,KoornneefL.Clinicalactivityscoreasaguideinthemanagementofpatientswithgraves‚Äôophthalmopathy.ClinEndocrinol(Oxf)(1997)47(1):9‚Äì14.doi:10.1046/j.1365-2265.1997.2331047.x12.KampmannE,DianaT,KanitzM,HoppeD,KahalyG.Thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroid-associated
orbitopathy:aprospectivestudy.IntJEndocrinol(2015)2015.doi:10.1155/2015/67819413.BahnRS.Graves‚Äôophthalmopathy.NEngJMed(2010)362(8):726‚Äì38.doi:10.1056/NEJMra090575014.SoroudiAE,GoldbergRA,McCannJD.Prevalenceofasymmetricexophthalmosingravesorbitopathy.OphthalmicPlastReconstrSurg(2004)20(3):224‚Äì5.doi:10.1097/01.iop.0000124675.80763.5a15.BartalenaL,BaldeschiL,DickinsonAJ,EcksteinA,Kendall-TaylorP,

---

### Chunk 23/30
**Article:** Hipotireioidismo (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.450

om TSH, T4L/T3L, anti-TPO/anti-Tg, prolactina.
- Tratar hipotireoidismo por 3‚Äì12 meses pode restaurar fertilidade; T3L baixo-normal em mulheres em T4 pode aumentar infertilidade; ajuste de T4 visando T3L alto-normal mostrou benef√≠cio em estudo pequeno (n=21).
### 22. SOP e tireoide
- Otimizar tireoide pode corrigir fen√≥tipos de hiperandrogenismo em SOP (acne, hirsutismo, anovula√ß√£o); monitorar andr√≥genos, SHBG, ovula√ß√£o.
### 23. Tireoide e depress√£o
- Em depress√£o: T4‚Üë, T3‚Üì, TRH‚Üë, TSH‚Üë; altera√ß√µes centrais de eixo.
- Autoimunidade (anti-TPO/anticorpos) associada a maiores escores de depress√£o; TSH/T4L n√£o correlacionaram.
- Considerar T3 adjuvante de forma criteriosa em sintomas persistentes com base em seguran√ßa e co-manejo psiqui√°trico.
### 24. Fibromialgia e hipotireoidismo tecidual
- Evid√™ncias sugerem regula√ß√£o inadequada tireoidiana como mecanismo; ~35% t√™m resist√™ncia perif√©rica a horm√¥nios tiroideanos; autoimunidade frequente (~35%).

---

### Chunk 24/30
**Article:** Leaky Gut As a Danger Signal for Autoimmune Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.450

SLE. Moreover, the development of lupus in wild-type mice (C57BL/6 or BALB/c) immunized with phospholipid-binding proteins can 
be facilitated by the administration of LPS (122¬ñ124). Conversely, inhibition of TLR4 results in reduced autoantibody production and lowered renal glomerular IgG deposits in lupus-prone mice (125, 126). Taken together, these data suggest that LPS stimula-tion and TLR4 activation as disease-initiating factors for SLE. 
Lipoteichoic acid (LTA), a component of the Gram-positive bacterial cell wall, can also promote lupus disease. e expression of TLR2, the receptor of LTA, has been reported to be increased in 
SLE patients (127). In lupus-prone mice, TLR2 activation triggers lupus nephritis, whereas TLR2 knockout attenuates lupus-like symptoms (125, 128¬ñ130).

---

### Chunk 25/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** results | **Similarity:** 0.449

susandautoimmunity‚Äìastudyof350women.BrJDermatol1988;118:41‚Äì46.57WallaceHJ.Lichensclerosusetatrophicus.TransStJohnsHospDerma-tolSoc1971;57:9‚Äì30.58RegauerS,ReichO.Earlyvulvarlichensclerosus:ahistologicalchal-lenge.Histopathology2005;47:340‚Äì347.59LeeA,BradfordJ,FischerG.Long-termmanagementofadultvulvarlichensclerosus:aprospectivecohortstudyof507women.JAMADer-matol2015;151:1061‚Äì1067.60CooperSM,AliI,BaldoM,WojnarowskaF.Theassociationoflichensclerosusanderosivelichenplanusofthevulvawithautoimmunedis-
ease:acase-controlstudy.ArchDermatol2008;144:1432‚Äì1435.61KalowitzBieberA,SteuerAB,MelnickLE,WongPW,KeltzPomeranzMK.Autoimmuneanddermatologicconditionsassociatedwithlichensclerosus.JAmAcadDermatol2021;85:228‚Äì229.62VirgiliA,MinghettiS,BorghiA,CorazzaM.Long-termmaintenancetherapyforvulvarlichensclerosus:theresultsofarandomizedstudy
comparingtopicalvitaminEwithanemollient.EurJDermatol2013;23:189‚Äì194.63ChiCC,KirtschigG,BaldoM,BrackenburyF,LewisF,WojnarowskaF.Topicalinterventionsforgen

---

### Chunk 26/30
**Article:** Remiss√£o do L√∫pus Atrav√©s da Medicina Funcional Integrativa (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.448

fotossensibilidade (rea√ß√£o cut√¢nea exacerbada ao sol) e uma dermatite diagnosticada como at√≥pica ou de contato.
    - Inicialmente, o l√∫pus foi descartado por ter o anti-DNA negativo, mas o autoanticorpo para SAF estava positivo, sem cl√≠nica associada. A √∫nica orienta√ß√£o foi evitar a exposi√ß√£o solar.
*   **Evolu√ß√£o e Tratamento Convencional**
    - Em 2011, no terceiro ano da faculdade de medicina, come√ßou a apresentar artrite em v√°rias articula√ß√µes (tornozelos, joelhos, m√£os, punhos, ombros).
    - Novos exames confirmaram autoanticorpos positivos, consumo de complementos e um padr√£o de FAN sugestivo de l√∫pus.
    - O tratamento foi iniciado com hidroxicloroquina e corticoides. A artrite melhorou, mas a dermatite e a plaquetopenia persistiram.
    - Em abril de 2014, no sexto ano da faculdade, desenvolveu uma vasculite cut√¢nea, caracterizando um surto mais grave. O tratamento foi intensificado com azatioprina e doses mais altas de prednisona.

---

### Chunk 27/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.447

nosis and to evaluate 
related symptoms and the therapy response (
Table1
) (
122
,
 
123
). An 
autoimmune disease assessment should beconducted, especially in 
case of positive clinical features for thyroid autoimmune diseases, type 
1 diabetes mellitus, rheumatoid arthritis or scleroderma (
13
,
 
124
).
Histopathological assessment is mostly not necessary, as the clinical 
picture can beenough for the diagnosis. Nevertheless, there are many 
situations where an histological examination should always 
beconsidered (
Table2
) (
124
). e biopsy should beperformed from 
active sclerotic skin areas and erosions that do not improve aer the 
therapy (
13
). Early, ulcerative or erythematous lesions are inadequate 
biopsy areas, as they present mostly an unspecied histological picture 
(
105
). Preceding treatment with topical corticosteroids can also erase 
typical histopathological changes (
5
).

---

### Chunk 28/30
**Article:** MFI - S√çNDROME P√ìS COVID - AULA 01 (1) (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.445

ab√≥lico: glicemia, hemoglobina glicada.
    - Tire√≥ide: TSH, FT4, anticorpos tireoidianos.
    - Prolactina e macroprolactina.
    - IGF-1, quando pertinente.
    - Histamina/DAO em suspeita mastocit√°ria.
  - Diagn√≥sticos diferenciais e comorbidades (autoimunidade, neurodegenera√ß√£o, dist√∫rbios do SNA).
- Tratamento baseado em mecanismos:
  - Personalizar anti-inflamat√≥rios, antioxidantes, suporte mitocondrial, moduladores do intestino, adapt√≥genos, horm√¥nios quando necess√°rio.
  - Integrar t√©cnicas som√°ticas (p. ex., microfisioterapia) para desautonomia/tosse.
  - Monitorar marcadores e ajustar.

## Pontos Cr√≠ticos e Exemplos Concretos
- Prolactina elevada p√≥s-COVID:
  - Frequentemente benigna; conduta expectante com macroprolactina; intervir apenas se sintom√°tica.
- Hipocortisolismo sem corticoide pr√©vio:
  - Suspeitar mimetismo anti-ACTH e dano adrenal via ACE2.

---

### Chunk 29/30
**Article:** S√≠ndrome dos Ov√°rios Polic√≠sticos - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.445

lica, espessamento carot√≠deo, maior risco de infarto/AVC; trombose venosa profunda (risco 2x).
- Sono, obesidade e fadiga: hipersonia, cansa√ßo, alta preval√™ncia de sobrepeso/obesidade.
- COVID-19: ind√≠cios de maior gravidade em SOP descompensada (hiperandrogenismo, baixa vitamina D, inflama√ß√£o cr√¥nica).
- Obst√©tricas e neonatais: maior abortamento, DM gestacional, hipertens√£o, pr√©-ecl√¢mpsia, parto prematuro; maior interna√ß√£o neonatal, malforma√ß√µes cardiovasculares/geniturin√°rias; hiperandrogenismo materno sem corre√ß√£o metab√≥lica associa-se a maior tend√™ncia de TDAH e autismo nos filhos.
- Oncol√≥gicas: maior risco de c√¢ncer de endom√©trio; poss√≠vel aumento de risco de c√¢ncer de mama.
- Desconhecimento: ~50% n√£o sabem que t√™m SOP, muitas s√≥ descobrem ap√≥s primeiras complica√ß√µes.
### 3.

---

### Chunk 30/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** other | **Similarity:** 0.444

unogenetic scenario. A 
positive family history of LS in rst-degree female relatives can befound in 
12% of patients (
29
). HLA-DR and DQ are supposed to beinvolved in the 
susceptibility and protection from LS (
30
). In children with VLS, HLA-DQ7 
was present in 66% of the cases, in comparison to 31% in controls. Although 
these children showed a low association with autoimmunity, up to 56% of 
their relatives presented another autoimmune disease (
31
). In both adult 
male and female patients, HLA-DQ7 has been observed to occur more 
frequently in LS (
32
,
 
33
). A study of UK women with VLS demonstrated 
an increased frequency of HLA-DR12 (DRB1*12) and a lower frequency 
of HLA-DR17 (DRB1*0301/04) compared to controls. Furthermore, 
HLA-DR and DQ could not beassociated with the time of onset of VLS, 
anatomical changes and localization of the skin lesions, and the response to 
topical glucocorticoids (
34
).

---

